Biofrontera Inc. Increase (Decrease) in Accounts Receivable
Biofrontera Inc. (BFRI) reported Increase (Decrease) in Accounts Receivable of -$1.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- Biofrontera Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $1.71M.
- Biofrontera Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$3.41M.
- Biofrontera Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $4.27M, a 768.29% increase year-over-year.
- Biofrontera Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$947.00K, a 167.45% decline year-over-year.
- Biofrontera Inc. increase (decrease) in accounts receivable for fiscal 2025 was $1.91M, a 505.40% increase from fiscal 2024.
- Biofrontera Inc. increase (decrease) in accounts receivable for fiscal 2024 was $315.00K, a 79.49% decline from fiscal 2023.
- Biofrontera Inc. increase (decrease) in accounts receivable for fiscal 2023 was $1.54M, a 2094.29% increase from fiscal 2022.
- Biofrontera Inc. increase (decrease) in accounts receivable for fiscal 2022 was $70.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.71M 10-Q · filed 2026-08-13 | $2.57M derived: sum of 3 quarters · filed 2026-08-13 | $1.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$3.41M 10-Q · filed 2026-05-14 | $859.00K derived: sum of 2 quarters · filed 2026-05-14 | -$88.00K derived: sum of 3 quarters · filed 2026-05-14 | -$176.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.33M derived: sum of 2 quarters · filed 2026-03-19 | $3.24M derived: sum of 3 quarters · filed 2026-08-13 | $1.91M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$947.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.03M derived: sum of 2 quarters · filed 2026-08-13 | -$2.37M 10-Q · filed 2025-11-12 | -$1.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.42M 10-Q · filed 2026-08-13 | -$926.00K derived: sum of 3 quarters · filed 2026-08-13 | $478.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.33M 10-Q · filed 2026-05-14 | -$838.00K derived: sum of 2 quarters · filed 2026-05-14 | $566.00K derived: sum of 3 quarters · filed 2026-05-14 | $561.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $492.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.90M derived: sum of 2 quarters · filed 2026-03-19 | $1.89M derived: sum of 3 quarters · filed 2026-03-19 | $315.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.40M derived: sum of 2 quarters · filed 2025-11-12 | -$177.00K 10-Q · filed 2025-11-12 | $1.16M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.58M 10-Q · filed 2025-08-13 | -$249.00K derived: sum of 3 quarters · filed 2025-08-13 | $1.45M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$1.58M 10-Q · filed 2025-05-15 | -$244.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.45M derived: sum of 3 quarters · filed 2025-05-15 | -$421.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.03M derived: sum of 2 quarters · filed 2025-03-20 | $1.16M derived: sum of 3 quarters · filed 2025-03-20 | $1.54M 10-K · filed 2025-03-20 |
| 2023-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$177.00K derived: sum of 2 quarters · filed 2024-11-14 | $204.00K 10-Q · filed 2024-11-14 | $2.38M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$1.49M 10-Q · filed 2024-08-14 | $690.00K derived: sum of 3 quarters · filed 2024-08-14 | $229.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $381.00K 10-Q · filed 2024-05-15 | $2.56M derived: sum of 2 quarters · filed 2024-05-15 | $2.10M derived: sum of 3 quarters · filed 2024-05-15 | -$979.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $1.72M derived: sum of 2 quarters · filed 2024-03-15 | -$1.36M derived: sum of 3 quarters · filed 2024-03-15 | $70.00K 10-K · filed 2024-03-15 |
| 2022-09-30 | -$461.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$3.54M derived: sum of 2 quarters · filed 2023-11-09 | -$2.11M 10-Q · filed 2023-11-09 | -$289.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$1.65M 10-Q · filed 2023-08-11 | $172.00K derived: sum of 3 quarters · filed 2023-10-03 | $461.00K derived: sum of 4 quarters · filed 2023-10-03 |
| 2022-03-31 | $1.43M 10-Q · filed 2023-05-12 | $3.25M derived: sum of 2 quarters · filed 2023-10-03 | $3.54M derived: sum of 3 quarters · filed 2023-10-03 | $3.55M derived: sum of 4 quarters · filed 2023-10-03 |
| 2021-12-31 | $1.82M derived: 8-K 12 month − 10-Q 9 month · filed 2023-10-03 | $2.11M derived: sum of 2 quarters · filed 2023-10-03 | $2.12M derived: sum of 3 quarters · filed 2023-10-03 | $612.00K 8-K · filed 2023-10-03 |
| 2021-09-30 | $289.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $299.00K derived: sum of 2 quarters · filed 2022-11-14 | -$1.21M 10-Q · filed 2022-11-14 | $996.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$1.50M 10-Q · filed 2022-08-12 | $707.00K derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | -$1.51M 10-Q · filed 2022-05-13 | $697.00K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-11 | -$1.17M 10-K · filed 2022-04-11 | ||
| 2020-09-30 | -$3.38M 10-Q · filed 2021-11-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |